Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCC's Cash to Debt is ranked higher than
93% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. CYCC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CYCC' s Cash to Debt Range Over the Past 10 Years
Min: 1  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.75
CYCC's Equity to Asset is ranked higher than
58% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYCC: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
CYCC' s Equity to Asset Range Over the Past 10 Years
Min: -3.51  Med: 0.76 Max: 0.88
Current: 0.75
-3.51
0.88
Interest Coverage No Debt
CYCC's Interest Coverage is ranked higher than
90% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CYCC' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -19.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1503.75
CYCC's Operating margin (%) is ranked lower than
81% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. CYCC: -1503.75 )
Ranked among companies with meaningful Operating margin (%) only.
CYCC' s Operating margin (%) Range Over the Past 10 Years
Min: -25222.48  Med: -4811.63 Max: -831.79
Current: -1503.75
-25222.48
-831.79
Net-margin (%) -1248.83
CYCC's Net-margin (%) is ranked lower than
80% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. CYCC: -1248.83 )
Ranked among companies with meaningful Net-margin (%) only.
CYCC' s Net-margin (%) Range Over the Past 10 Years
Min: -19110.14  Med: -4605.02 Max: -737.76
Current: -1248.83
-19110.14
-737.76
ROE (%) -72.46
CYCC's ROE (%) is ranked lower than
72% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. CYCC: -72.46 )
Ranked among companies with meaningful ROE (%) only.
CYCC' s ROE (%) Range Over the Past 10 Years
Min: -156.88  Med: -98.34 Max: -42.99
Current: -72.46
-156.88
-42.99
ROA (%) -53.68
CYCC's ROA (%) is ranked lower than
69% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. CYCC: -53.68 )
Ranked among companies with meaningful ROA (%) only.
CYCC' s ROA (%) Range Over the Past 10 Years
Min: -86.17  Med: -58.95 Max: -34.56
Current: -53.68
-86.17
-34.56
ROC (Joel Greenblatt) (%) -9441.48
CYCC's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. CYCC: -9441.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYCC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -10207.43  Med: -3822.33 Max: -1007.24
Current: -9441.48
-10207.43
-1007.24
Revenue Growth (3Y)(%) 92.80
CYCC's Revenue Growth (3Y)(%) is ranked higher than
93% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CYCC: 92.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYCC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -23 Max: 92.8
Current: 92.8
0
92.8
EBITDA Growth (3Y)(%) -35.40
CYCC's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CYCC: -35.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYCC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.2  Med: -31.7 Max: 13.8
Current: -35.4
-50.2
13.8
EPS Growth (3Y)(%) -36.40
CYCC's EPS Growth (3Y)(%) is ranked lower than
82% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CYCC: -36.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYCC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.8  Med: -32.3 Max: 19.3
Current: -36.4
-50.8
19.3
» CYCC's 10-Y Financials

Financials (Next Earnings Date: 2017-03-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CYCC Guru Trades in Q4 2015

Jim Simons 145,294 sh (New)
» More
Q1 2016

CYCC Guru Trades in Q1 2016

Jim Simons 279,094 sh (+92.09%)
» More
Q2 2016

CYCC Guru Trades in Q2 2016

Jim Simons 44,613 sh (+91.82%)
» More
Q3 2016

CYCC Guru Trades in Q3 2016

Jim Simons 163,913 sh (+267.41%)
» More
» Details

Insider Trades

Latest Guru Trades with CYCC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP6.159.766% Convertible Exchangeable Preferred Stock

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:VBIO, OTCPK:CVALF, OTCPK:ENZN, OTCPK:PRGB, OTCPK:NXTTF, NAS:CERU, NAS:STEM, NAS:CBLI, OTCPK:ONCYF, NAS:NEOT, AMEX:HEB, NAS:SBOT, NAS:CSBR, OTCPK:VDQSF, NAS:DPRX, NAS:EYEG, OTCPK:IMUN, NAS:ABIO, NAS:CLSN, AMEX:MSTX » details
Traded in other countries:UXI3.Germany,
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases.

Cyclacel Pharmaceuticals Inc was founded in August 13, 1996 and is incorporated in Delaware. The Company is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Its clinical development priorities are focused on sapacitabine only, its second drug candidate, seliciclib, is a novel, orally-available, CDK clinical development priorities are focused on sapacitabine as an orphan drug for the treatment of both Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS. The Company is currently evaluating sapacitabine in a Phase 3 study being conducted under a Special Protocol Assessment, or SPA, with the FDA for the front-line treatment of AML in the elderly. The Company is also exploring sapacitabine in Phase 2 studies for MDS, non-small cell lung cancer, or NSCLC, and chronic lymphocytic leukemia, or CLL and in a Phase 1 study in solid tumors in combination with seliciclib, another of its drug candidates. Sapacitabine has been evaluated in approximately 1,000 patients to date. In addition, in polo-like kinase, or PLK inhibitor program, the Company has discovered CYC140 and other small molecule inhibitors of PLK1, a kinase active during cell division, targeting the mitotic phase of the cell cycle. The Company retains all marketing rights for these compounds internationally.

Ratios

vs
industry
vs
history
P/B 0.75
CYCC's P/B is ranked higher than
95% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. CYCC: 0.75 )
Ranked among companies with meaningful P/B only.
CYCC' s P/B Range Over the Past 10 Years
Min: 0.22  Med: 1.95 Max: 13.13
Current: 0.75
0.22
13.13
P/S 12.11
CYCC's P/S is ranked lower than
52% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. CYCC: 12.11 )
Ranked among companies with meaningful P/S only.
CYCC' s P/S Range Over the Past 10 Years
Min: 5.02  Med: 67.01 Max: 9520
Current: 12.11
5.02
9520
Current Ratio 4.05
CYCC's Current Ratio is ranked lower than
51% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CYCC: 4.05 )
Ranked among companies with meaningful Current Ratio only.
CYCC' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.02 Max: 12.96
Current: 4.05
0.96
12.96
Quick Ratio 4.05
CYCC's Quick Ratio is ranked higher than
51% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. CYCC: 4.05 )
Ranked among companies with meaningful Quick Ratio only.
CYCC' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.02 Max: 12.96
Current: 4.05
0.96
12.96
Days Sales Outstanding 742.20
CYCC's Days Sales Outstanding is ranked lower than
99% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. CYCC: 742.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYCC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 568.15  Med: 777.81 Max: 6980.27
Current: 742.2
568.15
6980.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -60.40
CYCC's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. CYCC: -60.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYCC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -43 Max: 0
Current: -60.4
-144.5
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.03
CYCC's Price/Net Cash is ranked higher than
96% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 6.19 vs. CYCC: 1.03 )
Ranked among companies with meaningful Price/Net Cash only.
CYCC' s Price/Net Cash Range Over the Past 10 Years
Min: 0.55  Med: 2.34 Max: 9.34
Current: 1.03
0.55
9.34
Price/Net Current Asset Value 0.75
CYCC's Price/Net Current Asset Value is ranked higher than
98% of the 1006 Companies
in the Global Biotechnology industry.

( Industry Median: 5.65 vs. CYCC: 0.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYCC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.45  Med: 2.2 Max: 6.18
Current: 0.75
0.45
6.18
Price/Tangible Book 0.75
CYCC's Price/Tangible Book is ranked higher than
97% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CYCC: 0.75 )
Ranked among companies with meaningful Price/Tangible Book only.
CYCC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.41  Med: 2.13 Max: 5.9
Current: 0.75
0.41
5.9
Price/Median PS Value 0.18
CYCC's Price/Median PS Value is ranked higher than
94% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CYCC: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
CYCC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 1.01 Max: 118.93
Current: 0.18
0.12
118.93
Earnings Yield (Greenblatt) (%) 1764.24
CYCC's Earnings Yield (Greenblatt) (%) is ranked lower than
99.99% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. CYCC: 1764.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYCC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1362000.78  Med: 426.1 Max: 26714.3
Current: 1764.24
-1362000.78
26714.3

More Statistics

Revenue (TTM) (Mil) $0.99
EPS (TTM) $ -4.15
Beta5.07
Short Percentage of Float9.40%
52-Week Range $3.05 - 9.72
Shares Outstanding (Mil)4.25

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 2 11 54
EPS ($) -2.93 -5.48 -9.21 -1.26
EPS w/o NRI ($) -2.93 -5.48 -9.21 -1.26
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CYCC

Headlines

Articles On GuruFocus.com
Wilbur Ross Buys Two New Stakes in First Quarter Jun 15 2015 
Insider Cluster Buying Reported in Several Companies May 30 2013 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and... Dec 01 2016
7:05 am Cyclacel Pharma announces preclinical data 'demonstrating the therapeutic potential' of its... Dec 01 2016
Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer... Dec 01 2016
CYCLACEL PHARMACEUTICALS, INC. Financials Nov 23 2016
ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 23, 2016 Nov 23 2016
Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21,... Nov 21 2016
Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down Nov 18 2016
Here’s Why Cyclacel Pharmaceuticals Inc (CYCC) Could Have A Rough December Nov 18 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 14 2016
Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results Nov 14 2016
Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results Nov 14 2016
Q3 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close Nov 14 2016
Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results Nov 07 2016
Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results Nov 07 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Sep 12 2016
Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data... Sep 06 2016
Cyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical... Sep 06 2016
CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 30 2016
Movers and Shakers In Biotech: Cyclacel Pharmaceuticals Inc (CYCC) and Corium International Inc... Aug 23 2016
Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism Aug 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)